Furthermore, immunotherapy is a rapidly growing area of research in gastric cancer, and anti-programmed cell death 1 (PD-1) antibodies, such as nivolumab, sintilimab and camrelizumab, have been demonstrated to improve locally progressed overall survival and progression-free survival in patients with GC [7,8,9]. The gene discussed is PDCD1; the disease is gastric cancer.